MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Alterations of gait as an early marker of incipient alpha-synucleinopathy

    K-L. Weiß, S. Röttgen, A. Ophey, G. Fink, M. Sommerauer (Cologne, Germany)

    Objective: To investigate early motor signs of α-synucleinopathies in patients with isolated REM sleep behavior disorder (iRBD) using gait analysis. Background: iRBD is an early…
  • 2023 International Congress

    RNA editing contributes to the inflammatory astrocytic response in Parkinson’s disease.

    A. Wagen, K. D'Sa, M. Choi, S. Strohbuecker, G. Young, R. Reynolds, S. Garcia-Ruiz, Z. Chen, A. Ghareeb, J. Bayne, S. Rodriques, M. Horrocks, S. Gandhi, M. Ryten (London, United Kingdom)

    Objective: 1) Using an IPSC derived cell model to explore astrocytic responses alone and cocultured neurons to alpha-synuclein oligomer (αsynO) treatment.2) Determine the extent to…
  • 2023 International Congress

    Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone

    E. Ojeda-Lepe, S. García-Díaz, R. Díaz Belloso, L. Muñoz-Delgado, S. Jesús, MT. Periñán, B. Benítez Zamora, AD. Adarmes-Gómez, D. Macías-García, M. Martín-Bornez, M. Bonilla-Toribio, D. Buiza-Rueda, R. Pineda-Sánchez, F. Carrillo, P. Gómez-Garre, P. Mir (Seville, Spain)

    Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…
  • 2023 International Congress

    Efficacy of perampanel in paroxysmal kinesigenic dyskinesia

    Z. Li, X. Huang, L. Cao (Shanghai, China)

    Objective: To explore the efficacy and safety of perampanel in the treatment of paroxysmal kinesigenic dyskinesia (PKD) Background: Perampanel is a new type of antiepileptic…
  • 2023 International Congress

    An European-Canadian multinational evaluation of access to care in Parkinson disease: a patient perspective

    M. van Munster, E. Crighton, A. Sánchez-Ferro, J. Ferreira, R. Bouça, E. Ruzicka, D. Pedrosa, D. Grimes, T. Mestre (Marburg, Germany)

    Objective: To provide a multi-national perspective of people with Parkinson disease (PwPD) on access to healthcare and the impact of the COVID-19 pandemic on those…
  • 2023 International Congress

    Individual-specific brain functional connectivity mapping of therapeutic response in task-specific focal dystonia

    E. Gordon, K. Matthews, A. Meyer, S. Norris (St. Louis, USA)

    Objective: Determine therapeutic effects of botulinum toxin on functional connectivity in individuals with task-specific dystonia. Background: Isolated task-specific dystonia occurs during specific activities, but not…
  • 2023 International Congress

    Motor subtype stability and cognitive profiles in early Parkinson’s disease

    N. Chia, S. Ng, X. Choi, D. Heng, S. Neo, Z. Xu, K. Tay, W. Au, E. Tan, L. Tan (Singapore, Singapore)

    Objective: To examine the association between motor subtypes’ stability and cognitive assessment scores across three years in early Parkinson’s disease (PD). Background: Past studies have…
  • 2023 International Congress

    Hearing impairment and non-motor symptoms in Parkinson’s disease: association and impact on quality of life

    E. Garasto, M. Conti, A. Viziano, A. Stefani, M. Pierantozzi, NB. Mercuri, A. Moleti, R. Sisto, T. Schirinzi, R. Cerroni (Rome, Italy)

    Objective: The aim of the study was to investigate the possible correlation between non-motor symptoms (NMS) burden and quality of life (QoL) with hearing impairment…
  • 2023 International Congress

    Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking

    Q. Zhao (Shanghai, China)

    Objective: Based on the method of network pharmacology, this paper discusses the potential effects and mechanisms of SGD in the treatment of pain in PD. Background:…
  • 2023 International Congress

    Gender differences in REM Sleep Behavior Disorder in Parkinson’s disease

    EL. Ungureanu, ș. Diaconu, A. Zârnoveanu, R. Filip, M. Cușnir, B. Ciopleiaș, C. Falup-Pecurariu (Brasov, Romania)

    Objective: To study the gender differences in probable REM Sleep Behavior Disorder (RBD) and other sleep characteristics in a cohort of Parkinson’s disease (PD) patients.…
  • « Previous Page
  • 1
  • …
  • 613
  • 614
  • 615
  • 616
  • 617
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley